Torthaí cuardaigh - Lalezari, Jacob

Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab de réir Elneil, Sohier, Lalezari, Jacob P., Pourhassan, Nader Z.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy de réir Hatano, Hiroyu, Lampiris, Harry, Fransen, Signe, Gupta, Soumi, Huang, Wei, Hoh, Rebecca, Martin, Jeffrey N., Lalezari, Jacob, Bangsberg, David, Petropoulos, Christos, Deeks, Steven G.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects de réir Hanna, George J., Lalezari, Jacob, Hellinger, James A., Wohl, David A., Nettles, Richard, Persson, Anna, Krystal, Mark, Lin, Pinfang, Colonno, Richard, Grasela, Dennis M.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis de réir Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis de réir Brinson, Cynthia, Lalezari, Jacob, Latiff, Gulam H, Thompson, Melanie, Echevarría, Juan, Treviño-Pérez, Sandra, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Faigh an téacs iomlán Faigh an téacs iomlán

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis de réir Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-s... de réir Einstein, Mark H, Takacs, Peter, Chatterjee, Archana, Sperling, Rhoda S, Chakhtoura, Nahida, Blatter, Mark M, Lalezari, Jacob, David, Marie-Pierre, Lin, Lan, Struyf, Frank, Dubin, Gary

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis de réir Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarría, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Faigh an téacs iomlán Faigh an téacs iomlán

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with A... de réir Lalezari, Jacob P., Aberg, Judith A., Wang, Laurene H., Wire, Mary Beth, Miner, Richard, Snowden, Wendy, Talarico, Christine L., Shaw, Shuching, Jacobson, Mark A., Drew, W. Lawrence

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection de réir Lalezari, Jacob, Asmuth, David, Casiró, Arnaldo, Vargas, Hugo, Lawrence, Shannon, Dubuc-Patrick, Gloria, Chen, Jie, McCarville, Joseph, Pietropaolo, Keith, Zhou, Xiao-Jian, Sullivan-Bólyai, John, Mayers, Douglas

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody de réir Jacobson, Jeffrey M., Thompson, Melanie A., Lalezari, Jacob P., Saag, Michael S., Zingman, Barry S., D’Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults de réir Jacobson, Jeffrey M., Lalezari, Jacob P., Thompson, Melanie A., Fichtenbaum, Carl J., Saag, Michael S., Zingman, Barry S., D'Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study de réir Berkowitz, Elchonon M., Moyle, Graeme, Stellbrink, Hans-Jürgen, Schürmann, Dirk, Kegg, Stephen, Stoll, Matthias, El Idrissi, Mohamed, Oostvogels, Lidia, Heineman, Thomas C., Brockmeyer, Norbert, deJesus, Edwin, Esser, Stefan, Hawkins, Trevor, Lalezari, Jacob, Orkin, Chloe, Schneider, Stefan

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV-1 Coinfection de réir Sulkowski, Mark S., Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F., Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M., Symonds, William T., Subramanian, G. Mani, McHutchison, John G., Rodriguez-Torres, Maribel, Dieterich, Douglas

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection de réir Gulick, Roy M., Lalezari, Jacob, Goodrich, James, Clumeck, Nathan, DeJesus, Edwin, Horban, Andrzej, Nadler, Jeffrey, Clotet, Bonaventura, Karlsson, Anders, Wohlfeiler, Michael, Montana, John B., McHale, Mary, Sullivan, John, Ridgway, Caroline, Felstead, Steve, Dunne, Michael W., van der Ryst, Elna, Mayer, Howard

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab de réir Agresti, Nicholas, Lalezari, Jacob P., Amodeo, Phillip P., Mody, Kabir, Mosher, Steven F., Seethamraju, Harish, Kelly, Scott A., Pourhassan, Nader Z., Sudduth, C. David, Bovinet, Christopher, ElSharkawi, Ahmed E., Patterson, Bruce K., Stephen, Reejis, Sacha, Jonah B., Wu, Helen L., Gross, Seth A., Dhody, Kush

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing de réir Wei, Datsen George, Chiang, Vicki, Fyne, Elizabeth, Balakrishnan, Mini, Barnes, Tiffany, Graupe, Michael, Hesselgesser, Joseph, Irrinki, Alivelu, Murry, Jeffrey P., Stepan, George, Stray, Kirsten M., Tsai, Angela, Yu, Helen, Spindler, Jonathan, Kearney, Mary, Spina, Celsa A., McMahon, Deborah, Lalezari, Jacob, Sloan, Derek, Mellors, John, Geleziunas, Romas, Cihlar, Tomas

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial de réir Gnann, John W., Crumpacker, Clyde S., Lalezari, Jacob P., Smith, Jean A., Tyring, Stephen K., Baum, Kenneth F., Borucki, Michael J., Joseph, W. Patrick, Mertz, Gregory J., Steigbigel, Roy T., Cloud, Gretchen A., Soong, Seng-jaw, Sherrill, Lanette C., DeHertogh, Deborah A., Whitley, Richard J., Group, the Collaborative Antiviral Study Group (Casg)/aids Clinical Trials Group (Actg) Herpes Zoster Study

Faigh an téacs iomlán Faigh an téacs iomlán

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study de réir Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study de réir Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán